From The First Breath to the Golden Years: Respiratory Syncytial Virus Prevention in Infants and Older Adults
DOI:
https://doi.org/10.58931/cpct.2024.2127Abstract
Respiratory syncytial virus (RSV) is one of the most common respiratory infections observed in primary care. Although many think of RSV as a ‘common cold’, it is a serious health threat to certain populations, including children, particularly infants who are 6 months of age or younger, those with comorbidities, and older adults. With the increasing number of options to reduce the impact of RSV infections, including morbidity and mortality, it is important to recognize that primary care clinicians must be able to identify people at risk for RSV infection, effectively educate them on the potential impact of the condition, and identify strategies to lower the risk.
References
Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21(11):734-749. doi:10.1038/s41579-023-00919-w DOI: https://doi.org/10.1038/s41579-023-00919-w
Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 15(3). doi:10.7759/cureus.36342 DOI: https://doi.org/10.7759/cureus.36342
Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus—a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331-379. doi:10.1007/s12016-013-8368-9 DOI: https://doi.org/10.1007/s12016-013-8368-9
Canadian Paediatric Society. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Available from: https://cps.ca/en/documents/position/bronchiolitis [Accessed October 17, 2023]
NACI. Respiratory syncytial virus (RSV): Canadian Immunization Guide. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunizationguide-part-4-active-vaccines/respiratory-syncytial-virus.html [Published online March 28, 2023, Accessed October 18, 2023]
Surie D, Yuengling KA, DeCuir J, Zhu, Y, Gaglani M, Ginde AA, et al. Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(40):1083-1088. doi:10.15585/mmwr.mm7240a2 DOI: https://doi.org/10.15585/mmwr.mm7240a2
Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71(14):1574-1583. doi:10.1016/j.jacc.2018.02.013 DOI: https://doi.org/10.1016/j.jacc.2018.02.013
Juhn YJ, Wi CI, Takahashi PY, Ryu E, King KS, Hickman JA, et al. Incidence of respiratory syncytial virus infection in older adults before and during the COVID-19 Pandemic. JAMA Netw Open. 2023;6(1). doi:10.1001/jamanetworkopen.2022.50634 DOI: https://doi.org/10.1001/jamanetworkopen.2022.50634
Hamilton MA, Liu Y, Calzavara A, Sundaram ME, Djebli M, Darvin D, et al. Predictors of all-cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2. Influenza Other Respir Viruses. 2022;16(6):1072-1081. doi:10.1111/irv.13004 DOI: https://doi.org/10.1111/irv.13004
Haber N. Respiratory syncytial virus infection in elderly adults. Med Mal Infect. 2018;48(6):377-382. doi:10.1016/j.medmal.2018.01.008 DOI: https://doi.org/10.1016/j.medmal.2018.01.008
Branche AR, Saiman L, Walsh EE, Falsey AR, Jia H, Barrett A, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir Viruses. 2022;16(6):1151-1160. doi:10.1111/irv.13043 DOI: https://doi.org/10.1111/irv.13043
Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4 DOI: https://doi.org/10.15585/mmwr.mm7229a4
Food and Drug Administration. ABRYSVOTM Product Information. Available from: https://www.fda.gov/media/168889/download [Published online August 2023, Accessed December 12, 2023]
AREXVY® Product Monograph. GlaxoSmithKline, Canada. Available from: https://pdf.hres.ca/dpd_pm/00071904.PDF [Published online August 4, 2023, Accessed December 12, 2023]
Center for Disease Control and Prevention. Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over. Available from: https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html [Published online October 27, 2023, Accessed December 12, 2023]
Kampmann B, Madhi SA, Munjal I, Simoes EAF, Pahud BA, Llapur C, et al. Bivalent prefusion f vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464. doi:10.1056/NEJMoa2216480 DOI: https://doi.org/10.1056/NEJMoa2216480
Centers for Disease Control and Prevention. Healthcare Providers: RSV Vaccination for Pregnant People. Available from: https://www.cdc.gov/vaccines/vpd/rsv/hcp/pregnant-people.html [Published September 29, 2023, Accessed October 3, 2023]
Sun M, Lai H, Na F, Li S, Qiu X, Tian, J, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023;6(2). doi:10.1001/jamanetworkopen.2023.0023 DOI: https://doi.org/10.1001/jamanetworkopen.2023.0023
Canada’s Drug and Health Technology Agency. CADTH Health Technology Review: Nirsevimab (Beyfortus). Available from: https://www.cadth.ca/sites/default/files/hta-he/HC0059%20Nirsevimab%20for%20RSV%20prophylaxis-secured.pdf [Accessed October 18, 2023]
SYNAGIS® Product Monograph. AstraZeneca Canada, Inc. Available from: https://www.astrazeneca.com/content/dam/az-ca/downloads/productinformation/synagis-product-monograph-en.pdf [Date of Revision February 24, 2022, Accessed October 18, 2023]
BEYFORTUS™ Product Monograph. AstraZeneca Canada Inc. Available from: https://pdf.hres.ca/dpd_pm/00070439.PDF [Date of Initial Authorization: April 19, 2023, Accessed October 18, 2023]
Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sanchez, PJ, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920-925. doi:10.15585/mmwr.mm7234a4 DOI: https://doi.org/10.15585/mmwr.mm7234a4
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Primary Care Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
